A New Blog Series for Biologic Drug Developers
The outbreak of diseases like COVID-19 and the growth of new treatments for diseases like cancer have highlighted the importance of cooperation between Biologic Developers and their contract manufacturing partners. For EirGenix, health is important for all people. Under this belief, EirGenix established our CDMO to help clients leverage our team's experience and knowledge in developing their biologics that we learned from developing biosimilars and biobetters.
EirGenix's upholds the mission of providing clients with high-quality and cost-effective CDMO services and biologics. We do this to enhance the wellbeing of individuals and society, and improve the quality of life. Now more than ever, we need to foster education and dialogue to address the challenges and opportunities in drug development and commercialization.
A complex and strategic partnership
Today, the relationship between Biologic Developers and CDMOs is more collaborative and strategic. As a strategic partner, we need to work closely with our clients to ensure product quality, cost efficiency, and regulatory compliance. At EirGenix, we understand the value of building strong and successful partnerships with our customers. We have the expertise, capabilities, and global operations to support their drug programs from development to launch. We also have the insights and ideas to help overcome the industry’s most pressing issues: to improve output, lower costs, speed up production, and provide better access. We know that by working together we can help you achieve your goals.
Sharing our Knowledge and Expertise
To fulfill our mission, we are launching this knowledge platform – a new blog series where we will share our first-hand knowledge, experience, and best practices. This will be a place where you can learn from our team of experts, get inspired by our innovative solutions, and give you access to new science, capabilities, and ideas that will help you advance your drug programs. Thanks for your interest!
If you like what you see, please tell others!
Working with a CDMO can be both rewarding and challenging. However, some challenges must be considered in order to be truly successful. Let's take a...
Method development focuses on creating a reliable method, qualification evaluates its performance, and validation ensures it meets regulatory...
Behind every successful mAb lies a carefully optimized upstream development process that serves as the cornerstone for obtaining high-quality,...
Optimizing downstream process development for monoclonal antibodies requires a combination of scientific expertise, careful planning, and rigorous...
Technology transfer (TT) of therapeutic biologics is a complex and collaborative endeavor. Consider these nine critical areas to ensure a seamless...
Selecting the right pDNA supplier is a critical decision that can significantly impact the success of your work. Consider these 10 key factors to...
Learn the current innovations and trends in the development of ADCs focusing on three main aspects: linker technology, drug payloads, and...
Developing a bispecific mAb? There are many considerations and this blog points to key issues & describes a case study where EirGenix overcame...
Discover the intricate process of developing monoclonal antibodies and their crucial role in targeted therapies. From initial research to clinical...
Developing a mAb and looking to optimizing production, productivity and consistency to reduce your cost of goods sold (COGS)? Consider using N-1...
Developing a mAb? Have you considered these cell line development factors? Let EirGenix’s experience and wisdom guide you towards success!
Developing a mAb? Picking the right cell line is critical to your success. Make sure you review these factors!
Thank you for taking the time to read our article. We hope you found it useful and informative!